$Gossamer Bio (GOSS.US)$ Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH • Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH). • The firm has a $9 price target (~984% upside based on June 24 close). • Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
Rockhoundj : 你对FRGT有什么想法?$Freight Technologies (FRGT.US)$ ?
FattyChick 楼主 Rockhoundj : 从今年早些时候的最后一次RS开始,下一个RS即将到来。
FattyChick 楼主 Rockhoundj : 如果你真的想要获得一个职位,可以在0.108 - 0.11的时候入场。
止损点为0.136。
Rockhoundj FattyChick 楼主 : 我持有的数量略低于0.13
设置了严格的止损
Jenna Ragan : 这些看起来很不错
查看更多评论...